Medical Oncology Department, ICANS, Strasbourg, France.
Medical Oncology Department, Hôpital Saint Louis, Paris, France.
Curr Treat Options Oncol. 2024 Sep;25(9):1225-1237. doi: 10.1007/s11864-024-01252-x. Epub 2024 Aug 17.
This perspective underscores the evolution and significance of neoadjuvant therapy in breast cancer, tracing its history and efficacy in improving outcomes. It delves into the correlation between achieving complete response and long-term survival, emphasizing the predictive value of treatment response estimation. Neoadjuvant chemotherapy in HER2-positive early breast cancer, particularly with taxanes and anti-HER2 therapies, emerges as a cornerstone, offering enhanced breast conservation rates and prognostic insights. The focus on individualized care, tailored to treatment response, underscores the need for adaptive strategies. Additionally, the article discusses the ongoing debate surrounding anthracyclines' role and the benefits of dual HER2 blockade. Ultimately, advocating for a personalized approach, guided by treatment response assessment, ensures optimal outcomes in HER2-positive breast cancer management.
这一观点强调了新辅助疗法在乳腺癌中的发展和意义，追溯了它在改善治疗效果方面的历史和疗效。它深入探讨了完全缓解与长期生存之间的相关性，强调了治疗反应评估的预测价值。在 HER2 阳性早期乳腺癌中，新辅助化疗，特别是联合紫杉类药物和抗 HER2 治疗，成为一个基石，提高了保乳率并提供了预后信息。关注基于治疗反应的个体化治疗，突显了适应性策略的必要性。此外，文章还讨论了围绕蒽环类药物作用和双重 HER2 阻断益处的持续争论。最终，提倡基于治疗反应评估的个体化方法，可确保 HER2 阳性乳腺癌管理的最佳结果。
